Updated:
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a asset manager based in Carlsbad; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts...
Ionis Pharmaceuticals
Discover how we are enabling better futures for people living with serious disease through groundbreaking innovations. Learn about our mission here.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Additional offices
New Brunswick · Cleveland · Stockholm · New York · Cambridge
Sector focus
Frequently asked questions
Is Ionis Pharmaceuticals a family office or an asset manager?
Ionis Pharmaceuticals is a publicly traded biotechnology company (Nasdaq: IONS), not a family office or asset manager. Its focus is on developing RNA- and DNA-targeted medicines for serious diseases.
What investment stages does Ionis Pharmaceuticals target?
Ionis does not make investments in external companies. It develops its own drug candidates from discovery through clinical trials and seeks partnerships with larger pharmaceutical firms for late-stage development and commercialization.
Who leads investment decisions at Ionis Pharmaceuticals?
CEO Brett P. Monia leads the company's strategic direction. Research and development decisions are made by internal scientific leadership, including Chief Scientific Officer Frank Bennett (per company filings, 2025).
How does Ionis Pharmaceuticals source its drug pipeline?
Ionis internally discovers and develops drug candidates using its proprietary antisense technology platform. The company also engages in partnerships and licensing agreements with other biopharma firms to expand its pipeline.
What therapeutic areas does Ionis Pharmaceuticals focus on?
Ionis concentrates on neurology, cardiometabolic disorders, and rare genetic diseases. The company also explores select high-need conditions where its RNA-targeting approach may offer a first-in-class treatment.
Does Ionis Pharmaceuticals explicitly avoid any sectors?
Ionis focuses strictly on RNA- and DNA-targeted therapeutics. It does not operate in oncology, vaccines, or small molecule drugs outside its core platform (per the firm's pipeline disclosures, 2025).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: